Length of time periods in treatment effect descriptions and willingness to initiate preventive therapy: a randomised survey experiment

BackgroundCommon measures used to describe preventive treatment effects today are proportional, i.e. they compare the proportions of events in relative or absolute terms, however they are not easily interpreted from the patient’s perspective and different magnitudes do not seem to clearly discriminate between levels of effect presented to people.MethodsIn this randomised cross-sectional survey experiment, performed in a Swedish population-based sample (n = 1041, response rate 58.6%), the respondents, aged between 40 and 75 years were given information on a hypothetical preventive cardiovascular treatment. Respondents were randomised into groups in which the treatment was described as having the effect of delaying a heart attack for different periods of time (Delay of Event, DoE): 1 month, 6 months or 18 months. Respondents were thereafter asked about their willingness to initiate such therapy, as well as questions about how they valued the proposed therapy.ResultsLonger DoE:s were associated with comparatively greater willingness to initiate treatment. The proportions accepting treatment were 81, 71 and 46% when postponement was 18 months, 6 months and 1 month respectively. In adjusted binary logistic regression models the odds ratio for being willing to take therapy was 4.45 (95% CI 2.72–7.30) for a DoE of 6 months, and 6.08 (95% CI 3.61–10.23) for a DoE of 18 months compared with a DoE of 1 month. Greater belief in the necessity of medical treatment increased the odds of being willing to initiate therapy.ConclusionsLay people’s willingness to initiate preventive therapy was sensitive to the magnitude of the effect presented as DoE. The results indicate that DoE is a comprehensible effect measure, of potential value in shared clinical decision-making.

[1]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[2]  R. Dobson,et al.  Cardiovascular Morbidity Associated with Nonadherence to Statin Therapy , 2005, Pharmacotherapy.

[3]  Dorte Gyrd-Hansen,et al.  Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey , 2007, BMC Medical Informatics Decis. Mak..

[4]  G. Elwyn,et al.  Communicating risk reductions. Researchers should present results with both relative and absolute risks. , 1999, BMJ.

[5]  E. Akl,et al.  Using alternative statistical formats for presenting risks and risk reductions. , 2011, The Cochrane database of systematic reviews.

[6]  Matteo Bottai,et al.  Laplace regression with censored data , 2010, Biometrical journal. Biometrische Zeitschrift.

[7]  I. Åkerlind,et al.  Beliefs about medicines and self-reported adherence among pharmacy clients. , 2007, Patient education and counseling.

[8]  P. Thompson,et al.  Magnetic resonance imaging of left atrial thrombus , 2002, Heart.

[9]  Jesper Bo Nielsen,et al.  Number needed to treat: easily understood and intuitively meaningful? Theoretical considerations and a randomized trial. , 2002, Journal of clinical epidemiology.

[10]  L. Callister,et al.  Patient‐centered care and adherence: Definitions and applications to improve outcomes , 2008, Journal of the American Academy of Nurse Practitioners.

[11]  Kim Brixen,et al.  Expressing effects of osteoporosis interventions in terms of postponing of fractures , 2002, European Journal of Clinical Pharmacology.

[12]  Paul M. Sniderman,et al.  Innovations in Experimental Design in Attitude Surveys , 1996 .

[13]  I. Åkerlind,et al.  General beliefs about medicines among doctors and nurses in out-patient care: a cross-sectional study , 2009, BMC family practice.

[14]  D. Nease,et al.  Adherence to Maintenance-Phase Antidepressant Medication as a Function of Patient Beliefs About Medication , 2005, The Annals of Family Medicine.

[15]  P. Lytsy,et al.  Patient expectations on lipid-lowering drugs. , 2007, Patient education and counseling.

[16]  P. Ubel,et al.  Helping patients decide: ten steps to better risk communication. , 2011, Journal of the National Cancer Institute.

[17]  Kim Brixen,et al.  A randomized trial of laypersons' perception of the benefit of osteoporosis therapy: number needed to treat versus postponement of hip fracture. , 2003, Clinical therapeutics.

[18]  P. Lytsy,et al.  Adherence to and beliefs in lipid-lowering medical treatments: a structural equation modeling approach including the necessity-concern framework. , 2013, Patient education and counseling.

[19]  J. Weinman,et al.  The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication , 1999 .

[20]  K. Alexander,et al.  Association between patient beliefs and medication adherence following hospitalization for acute coronary syndrome. , 2011, American heart journal.

[21]  Judith Covey,et al.  A Meta-analysis of the Effects of Presenting Treatment Benefits in Different Formats , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[22]  C. Cannon,et al.  Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial , 2017, Open Heart.

[23]  Brian J. Gaines,et al.  The Logic of the Survey Experiment Reexamined , 2007, Political Analysis.

[24]  J. Sundström,et al.  Treatment effect expressed as the novel Delay of Event measure is associated with high willingness to initiate preventive treatment - A randomized survey experiment comparing effect measures. , 2016, Patient education and counseling.

[25]  Ivar Kristiansen,et al.  Different Ways to Describe the Benefits of Risk-Reducing Treatments , 2007, Annals of Internal Medicine.

[26]  A. Hammond,et al.  Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. , 2005, Rheumatology.

[27]  S. Radloff,et al.  The effect of an educational intervention on patients' knowledge about hypertension, beliefs about medicines, and adherence. , 2009, Research in social & administrative pharmacy : RSAP.

[28]  D. Armstrong,et al.  Patients' responses to risk information about the benefits of treating hypertension. , 2001, The British journal of general practice : the journal of the Royal College of General Practitioners.

[29]  K. Alexander,et al.  Changes in beliefs about medications during long-term care for ischemic heart disease. , 2010, American heart journal.

[30]  J. Chan,et al.  Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. , 2004, British journal of clinical pharmacology.

[31]  I. Åkerlind,et al.  Different development of general beliefs about medicines during undergraduate studies in medicine, nursing and pharmacy. , 2009, Patient education and counseling.

[32]  M. Barry,et al.  Shared decision making--pinnacle of patient-centered care. , 2012, The New England journal of medicine.

[33]  J. Kragstrup,et al.  Danish GPs' perception of disease risk and benefit of prevention. , 2002, Family practice.

[34]  P. Burkhart,et al.  Adherence to long-term therapies: evidence for action. , 2003, Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing.

[35]  Katharina Stibrant Sunnerhagen,et al.  Person-Centered Care — Ready for Prime Time , 2011, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[36]  C D Naylor,et al.  Communicating the Benefits of Chronic Preventive Therapy , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.

[37]  N. Steel Communicating risk reductions. Modifying risk is different to treating illness. , 1999, BMJ.

[38]  Jesper Nielsen,et al.  Laypersons' understanding of relative risk reductions: Randomised cross-sectional study , 2008, BMC Medical Informatics Decis. Mak..

[39]  K. Andersson,et al.  Beliefs about Medicines among Swedish Pharmacy Employees , 2006, Pharmacy World and Science.

[40]  D. Gyrd-Hansen,et al.  Discounting life-years: whither time preference? , 1998, Health economics.

[41]  Christine A. Lee,et al.  The Illness Perceptions and Treatment Beliefs of Individuals with Severe Haemophilia and their Role in Adherence to Home Treatment , 2003 .

[42]  J. Sundström,et al.  A proposal for an additional clinical trial outcome measure assessing preventive effect as delay of events , 2012, European Journal of Epidemiology.

[43]  P A Raffle,et al.  Coronary heart-disease and physical activity of work. , 1953, Lancet.

[44]  R. Green,et al.  Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. , 2011, Genetic testing and molecular biomarkers.

[45]  K. Eagle,et al.  Adherence to Medications by Patients After Acute Coronary Syndromes , 2005, The Annals of pharmacotherapy.

[46]  John Weinman,et al.  Self-regulation and Self-management in Asthma: Exploring The Role of Illness Perceptions and Treatment Beliefs in Explaining Non-adherence to Preventer Medication , 2002 .